ASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (audio)
- Author
- cancerGRACE - H. Jack West, MD
- Published
- Wed 12 Sep 2012
- Episode Link
- http://cancergrace.libsyn.com/asco-2012-lc-highlights-dr-joel-neal-on-the-lux-lung-3-trial-of-afatinib-vs-chemo-for-egfr-mutation-positive-advanced-nsclc-audio
Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
